VBLT Vascular Biogenics

VBL Therapeutics to Report First Quarter 2020 Financial Results on May 14

VBL Therapeutics to Report First Quarter 2020 Financial Results on May 14

TEL AVIV, Israel, May 04, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, May 14, 2020 at 8:30am Eastern Time to report first quarter ended March 31, 2020 financial results and to provide a corporate update.

 
Thursday May 14th @ 8:30amET

From the US:  877-407-9208
International: 201-493-6784
Israel:  1 809 406 247
Conference ID: 13703295
Webcast: 
   



About VBL

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications.

INVESTOR CONTACT:

Michael Rice

LifeSci Advisors, LLC

(646) 597-6979

EN
04/05/2020

Underlying

VBLTVascular Biogenics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vascular Biogenics

 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Announces Results of Annual and Special Shareholder M...

VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its shareholders voted to approve the previously announced proposed merger (the “Merger”) with Notable Labs, Inc. (“Notable”), at the annual and special meeting (...

October 12, 2023 1 EN
 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual a...

VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting Shareholders of record as of September 5, 2023 are eligible to vote at the VBL Shareholder Meeting on October 12, 2023 MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annual and special meeting (the “Meeting”) for shareholders of record as of September 5, 2023. All VBL shareholders, regardless of...

October 4, 2023 1 EN
 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Announces that S-4 Registration Statement for Propose...

VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced that its registration statement on Form S-4 in connection with the proposed merger with Notable Labs, Inc. (“Notable”) has been declared effective by the U.S. Securities and Exchange Commission (“SEC”...

September 6, 2023 1 EN
 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Pro...

VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Merger with Notable expected to close in late September or October, subject to VBL’s S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30, 2023 MODI’IN, Israel and NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update. “We continue to make good progress towards the closing of o...

August 14, 2023 1 EN
 PRESS RELEASE
Free
VBLT Vascular Biogen...

VBL Therapeutics Reports First Quarter 2023 Financial Results and Prov...

VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction in Q3 2023, subject to SEC review and shareholder approvals MODI’IN, Israel and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today announced financial results for the first quarter ended March 31, 2023, and provided a corporate update. “During the first quarter, we made continued progress in the steps we are taking to maximize shareholder value and ar...

May 15, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch